Opko Health Inc (OPK) : 3 brokerage houses believe that Opko Health Inc (OPK) is a Strong Buy at current levels. 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Opko Health Inc (OPK). Zacks Investment Research suggests a Sell with a rank of 4.The median of all the 5 Wall Street Analysts endorse the stock as a Buy with a rating of 1.8.
Opko Health Inc (OPK) : The highest short term price target forecast on Opko Health Inc (OPK) is $20 and the lowest target price is $10. A total of 4 equity analysts are currently covering the company. The average price of all the analysts is $15.25 with a standard deviation of $4.27.
Opko Health Inc (NYSE:OPK): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $9.47 and $9.41 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $9.87. The buying momentum continued till the end and the stock did not give up its gains. It closed at $9.85, notching a gain of 3.03% for the day. The total traded volume was 4,692,133 . The stock had closed at $9.56 on the previous day.
Also, In the latest statement by the brokerage house, Deutsche Bank maintains its outlook on Opko Health Inc (NYSE:OPK). The current rating of the shares is Hold, according to the research report released by the firm. The brokerage firm lowers the price target from $11 per share to $10 per share. The rating by the firm was issued on June 16, 2016. The company shares have dropped -41.53% from its 1 Year high price. On Jul 24, 2015, the shares registered one year high at $19.20 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $9.76 and the 200 Day Moving Average price is recorded at $9.69.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.